NCT07566650Not yet recruiting
High-Intensity Transcranial Alternating Current Stimulation (Hi-tACS) for Hypertension: A Randomized Controlled Trial
A Randomized Controlled Trial of High-Intensity Transcranial Alternating Current Stimulation (Hi-tACS) for the Treatment of Essential Hypertension
Source: ClinicalTrials.gov · Last updated 5 May 2026
Brief summary (registry, in English)
This study focuses on individuals with primary hypertension, with the main objective of investigating the effectiveness and safety of high-intensity transcranial alternating current stimulation (Hi-tACS) as a non-invasive, non-pharmacological treatment for hypertension
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 16 Apr 2026
- Start date
- 1 May 2026
- Primary completion date
- 1 Oct 2027
- Lead sponsor
- Xuanwu Hospital, Beijing
- Diseases
- High blood pressure
- NCT number
- NCT07566650
What you commit to
- Study type: Interventional
- Planned participants: 50
- From 1 May 2026 to the primary completion date, 1 Oct 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participation in another clinical trial involving an investigational product or device within 30 days prior to screening.
Other illness
- Resistant hypertension (blood pressure uncontrolled despite adherence to ≥3 antihypertensive drugs of different classes at optimal doses, including a diuretic ), or known secondary hypertension.
- Uncontrolled sleep apnea syndrome, active infectious diseases, chronic wasting diseases, or significant cognitive impairment.
- Current major psychiatric disorder as assessed by the Mini-International Neuropsychiatric Interview (M.I.N.I.).
- Contraindications to tACS or MRI: implanted electronic devices, intracranial metal implants, or known history of seizures.
- Any condition that, in the opinion of the investigator, would jeopardize the patient's safety or compliance with the study protocol, or interfere with data interpretation.
Lab values
- History of severe cardiovascular or cerebrovascular disease (e.g., myocardial infarction, stroke, heart failure NYHA Class III-IV) within the past 6 months, or severe hepatic or renal dysfunction (defined as ALT/AST \>3× upper limit of normal \[ULN\], or eGFR \<30 mL/min/1.73 m²).
Other
- Women who are pregnant, breastfeeding, or planning pregnancy during the study period.
- Skin lesions, eczema, or broken skin at the intended electrode placement sites.
Who the study is looking for
- Clinical diagnosis of primary hypertension (Grade 1-3) as defined by the Chinese Hypertension Guidelines (Revised Edition 2024).
- For females of childbearing potential, agreement to use contraception during the study.
- Willing and able to comply with study procedures and provide written informed consent.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Xuanwu Hospital, Capital Medical University Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.